A pricing for everyone
Our pricing is based on the number of users. Whatever the size of your company, we have you covered !
- 1-Month Plan
- 3-Month Plan
- Most popular1-Year Plan
|1-Month Plan||3-Month Plan|| |
Most popular1-Year Plan
180 €16% OFF
600 €24% OFF
|1 user||72 €||180 €||600 €|
|2—5 users||144 €||360 €||1 200 €|
|6—14 users||240 €||600 €||2 000 €|
|15—49 users||360 €||900 €||3 000 €|
|50 and + users||480 €||1 200 €||4 000 €|
|Plan discount||-||16% OFF||24% OFF||Buy lastest report||Buy 3-Month Plan||Buy 1-Year Plan|
3 Month Plan
1 Year Plan
* Value Added Tax (VAT) may apply depending on the country where the Client is established, as defined in EU Directive 2006/112/EC (articles 44 and 196) and in the French Tax Code (CGI articles 259 and 283-2):
- Business Clients established in France: French VAT (20%) applies
- Business Clients established in other EU Member States: Clients are required to provide their EU VAT Number and to pay applicable VAT in their respective countries (reverse charge procedure).
- Business Clients established outside the EU: Clients may be required to pay applicable VAT or Sales Tax equivalent in their country, if applicable.
- Other clients: Please refer to our General Conditions.
The latest news on pharmacovigilance regulatory requirements in your mailbox, every month. 100 % free.
What they say
For many years, my company has subscribed to Safety ObserverIt is a very valuable and structured tool. It is keeping us up to date with new and updated regulatory requirements so we can take appropriate actions to ensure compliance.
Safety Observer serves as our company’s primary source for Regulatory PV updates.All PV employees have access and the comprehensive content in each issue is discussed on a monthly “Safety Observer Meeting”.
The Regulatory Intelligence Reports received monthly allow us to be more efficient in our regulatory monitoringThe reports contain all the information necessary to meet our requirements. The summaries and links contained for each item make it a clear and practical document, allowing us to save a lot of time.
Our Safety Observer monthly review is part of our company’s safety specific Regulatory Watch process to ensure that changes in the regulatory landscape are captured and internal SOPs updated accordingly
For five years now I have been reading the Safety Observer and will continue to do so.Even newsletters from large Pharmaceutical Associations cannot rival the in-depth coverage of such a long list of salient PV topics, as does the Safety Observer. The information contained is up-to-date, relevant to all decision makers in PV – and presented in a no-nonsense style that does not need precious time to understand the changes made: Succinct and relevant.
As one of its earliest subscribers, I can testify of the high level of completeness and quality of this regulatory screening.Each month, it provides in one look all the necessary updates I require to perform my daily activities.
I have discovered Safety Observer in 2016 and since then I am the most loyal fan of it.This magazine is able to replace the entire regulatory intelligence department in your organization. Subscription to Safety Observer is the easiest and most efficient way to keep up with the speed of safety regulation changes on a global level
Subscribing to the Safety Observer has given me relevant updates in a concise, accurate and easy manner in order to be kept up to date in my day to day Quality Assurance activities internally and externally.The format has enabled easy understanding and the accessibility to the source document has made it easier to document my self training. I am extremely pleased with the service provided.
Safety Observer is an effective and essential link in our regulatory intelligence,particularly in the constantly changing clinical research environment
Safety Observer has proven to us to be a reliable and reputable resource allowing us to remain current on new regulatory guidance.Safety Observer has also been instrumental in alerting us to crucial Drug Safety Signal Detection publications and literature, which have had a direct impact on improving and bolstering the attentiveness of our pharmacovigilance activities.